Ifinatamab Deruxtecan provides a B7-H3-targeting antibody-drug conjugate (ADC) for cancer and oncology research. It combines a B7-H3-directed monoclonal antibody with a deruxtecan (DXd) topoisomerase I inhibitor payload for targeted cytotoxicity and ADC studies.
Key Features and Benefits
- B7-H3-Targeting ADC: Combines a B7-H3-directed monoclonal antibody with a cytotoxic DXd payload specifically for targeted cancer research.
- DXd Payload: Contains a potent topoisomerase I inhibitor designed specifically for intracellular delivery through the ADC platform.
- B7-H3 Recognition: Supports studies of B7-H3 expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a cleavable linker specifically designed to facilitate intracellular release of the DXd payload following cellular uptake.
- Targeted Payload Delivery: Supports investigation of antibody-mediated DXd delivery to B7-H3-expressing cancer cells.
- DNA Damage Mechanism: DXd inhibits topoisomerase I, specifically supporting studies of DNA damage and ADC-mediated cytotoxic responses.
- ADC Research Platform: Enables investigation of target engagement, internalization, payload release, and cellular activity.
Applications
- B7-H3-Positive Cancer Research: Supports studies involving tumors that express the B7-H3 cell-surface protein.
- Small Cell Lung Cancer Research: Useful for investigating B7-H3-targeted ADC strategies in small cell lung cancer models.
- Solid Tumor Research: Supports studies of B7-H3-directed targeting across relevant solid tumor models.
- ADC Research: Useful for studying antibody targeting, internalization, payload delivery, and cytotoxic activity.
- Targeted Cancer Research: Supports investigation of antibody-mediated delivery of DXd to cancer cells.
- Cell-Based Cancer Assays: Useful for evaluating B7-H3-dependent binding, internalization, and cellular responses.
- Mechanism-of-Action Studies: Supports investigation of B7-H3 targeting and topoisomerase I inhibition.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures specifically for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Ifinatamab Deruxtecan combines B7-H3-directed antibody targeting with a DXd topoisomerase I inhibitor payload and specifically supports B7-H3-positive cancer, small cell lung cancer, ADC, and targeted drug delivery research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
